Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul 30;21(15):5439.
doi: 10.3390/ijms21155439.

Proteomics and Metabolomics for Cystic Fibrosis Research

Nara Liessi  1 , Nicoletta Pedemonte  2 , Andrea Armirotti  1 , Clarissa Braccia  3
Affiliations
Review

Proteomics and Metabolomics for Cystic Fibrosis Research

Nara Liessi et al. Int J Mol Sci. .

Abstract

The aim of this review article is to introduce the reader to the state-of-the-art of the contribution that proteomics and metabolomics sciences are currently providing for cystic fibrosis (CF) research: from the understanding of cystic fibrosis transmembrane conductance regulator (CFTR) biology to biomarker discovery for CF diagnosis. Our work particularly focuses on CFTR post-translational modifications and their role in cellular trafficking as well as on studies that allowed the identification of CFTR molecular interactors. We also show how metabolomics is currently helping biomarker discovery in CF. The most recent advances in these fields are covered by this review, as well as some considerations on possible future scenarios for new applications.

Keywords: biomarker discovery; cystic fibrosis; interactomics; metabolomics; post-translational modifications; proteomics.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
(A) Cartoon showing the pathway from the genotype to the phenotype. (B) Schematic representation of untargeted proteomics and metabolomics workflows.
Figure 2
Figure 2
Summary and outcomes of four of the cystic fibrosis transmembrane conductance regulator (CFTR) interactomic experiments highlighted in this review.
Figure 3
Figure 3
Representation of CFTR structure at the plasma membrane with known CFTR PTMs indicated in the primary sequence.
See this image and copyright information in PMC

References

    1. Ratjen F., Döring G. Cystic fibrosis. Lancet. 2003;361:681–689. doi: 10.1016/S0140-6736(03)12567-6. - DOI - PubMed
    1. Hwang T.C., Yeh J.T., Zhang J., Yu Y.C., Yeh H.I., Destefano S. Structural mechanisms of CFTR function and dysfunction. J. Gen. Physiol. 2018;150:539–570. doi: 10.1085/jgp.201711946. - DOI - PMC - PubMed
    1. Scanlin F.T., Glick M.C. Terminal glycosylation in cystic fibrosis. Biochim. Biophys. Acta. 1999;1455:241–253. doi: 10.1016/S0925-4439(99)00059-9. - DOI - PubMed
    1. Vergani P., Lockless S.W., Nairn A.C., Gadsby D.C. CFTR channel opening by ATP-driven tight dimerization of its nucleotide-binding domains. Nature. 2005;433:876–880. doi: 10.1038/nature03313. - DOI - PMC - PubMed
    1. Derichs N. Targeting a genetic defect: Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis. Eur. Respir. Rev. 2013;22:58–65. doi: 10.1183/09059180.00008412. - DOI - PMC - PubMed

MeSH terms

Substances